Adults 18 to 80, any sex, with Brief Video-based Intervention or Non Intervention Control. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Help-seeking BehaviorPrimary· Assessed at baseline and post-intervention (both day 1), first follow-up (day 14), and second follow-up (day 30)
Measured with the Attitudes Towards Seeking Professional Psychological Help Scale (ATSPPH) - total scores range from 3 to 12, with higher scores indicating greater treatment-seeking intentions
Baseline
Group
Value
95% CI
Video-based Intervention
8.2
7.9 – 8.5
Assessment Only
8.5
8.1 – 8.9
Post-intervention
Group
Value
95% CI
Video-based Intervention
9.3
9.0 – 9.6
Assessment Only
8.7
8.2 – 9.1
First follow-up (day 14)
Group
Value
95% CI
Video-based Intervention
9.7
9.4 – 10.0
Assessment Only
9.3
8.9 – 9.7
Second follow-up (day 30)
Group
Value
95% CI
Video-based Intervention
9.4
9.1 – 9.7
Assessment Only
9.1
8.8 – 9.5
Generalized Anxiety Disorder-7 (GAD-7)Primary· Assessed at baseline, 14-day follow-up, and 30-day follow-up
Measured with the GAD-7 scale - total scores range from 0 to 21, with higher scores indicating greater self-reported anxiety
Baseline (day 1)
Group
Value
95% CI
Video-based Intervention
7.6
± 5.9
Assessment Only
6.7
± 6.1
First follow-up (day 14)
Group
Value
95% CI
Video-based Intervention
6.9
± 6.0
Assessment Only
5.9
± 5.2
Second follow-up (day 30)
Group
Value
95% CI
Video-based Intervention
6.5
± 5.7
Assessment Only
5.4
± 5.3
Patient Health Questionnaire-9 (PHQ-9)Primary· Assessed at baseline, 14-day follow-up, and 30-day follow-up
Measured with PHQ-9 - total scores range from 0 to 27; higher scores indicate greater self-reported depression
Baseline (day 1)
Group
Value
95% CI
Video-based Intervention
7.9
± 6.6
Assessment Only
6.6
± 5.6
First follow-up (day 14)
Group
Value
95% CI
Video-based Intervention
7.4
± 6.7
Assessment Only
6.0
± 5.7
Second follow-up (day 30)
Group
Value
95% CI
Video-based Intervention
7.0
± 6.2
Assessment Only
5.4
± 5.7
Primary Care Posttraumatic Stress Disorder (PC-PTSD) ScreenPrimary· Assessed at baseline, 14-day follow-up, and 30-day follow-up
Measured with the PC-PTSD for DSM-5 - total scores range from 0 to 5, with higher scores indicating greater self-reported PTSD symptoms
Baseline (day 1)
Group
Value
95% CI
Video-based Intervention
1.9
± 1.6
Assessment Only
1.8
± 1.7
First follow-up (day 14)
Group
Value
95% CI
Video-based Intervention
1.8
± 1.6
Assessment Only
1.2
± 1.5
Second follow-up (day 30)
Group
Value
95% CI
Video-based Intervention
1.7
± 1.7
Assessment Only
1.4
± 1.6
Moral Injury Events Scale (MIES)Primary· Assessed at baseline, 14-day follow-up, and 30-day follow-up
Measured with the MIES - scores range from 9 to 36, with higher scores indicating greater moral injury
Baseline (day 1)
Group
Value
95% CI
Video-based Intervention
18.1
± 6.4
Assessment Only
17.1
± 6.6
First follow-up (day 14)
Group
Value
95% CI
Video-based Intervention
18.1
± 6.8
Assessment Only
16.5
± 6.3
Second follow-up (day 30)
Group
Value
95% CI
Video-based Intervention
17.5
± 6.7
Assessment Only
16.5
± 6.9
Sponsor's own description
The overarching goal of this study is to examine the efficacy of a brief video intervention in reducing stigma and fear, and improving help-seeking behavior, among health care providers (N=1,200), with pre- post- and follow-up assessments (at day 14 and day 30). Participants will be recruited via Amazon Turk and randomly assigned to either a) a video-based intervention (day 1 and a "booster intervention" of the same content on day 14 of the study) featuring the personal story of a health care provider during COVID-19 pandemic, his/her struggles and barriers to care, (b) video-based intervention (day 1 only), and a written description of the same story on day 14 (c) no-intervention control arm (questionnaires only).
The invetsigators aim to (1) determine whether video-based intervention reduce stigma and fear, and increase help-seeking behavior in relation to COVID-19 among health care providers, and (2) compare high-risk areas (e.g., NY) to low-risk areas (e.g., Montana) on intervention outcomes, and (3) test whether symptoms of depression, anxiety, PTSD and Moral Injury (measured by the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7), the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) and the Moral Injury Events Scale (MIES)) would change over time.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Research Foundation for Mental Hygiene, Inc.
Last refreshed: 14 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04497415.